BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Hanmi partners with American biotech company to develop multiple bispecific antibodies.

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : September 17, 2019, 13:13 | Updated : September 17, 2019, 13:13
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Hanmi]


SEOUL -- Undaunted by a series of business setbacks, Hanmi Pharmaceutical, a major drugmaker in South Korea, embarked on a new project to introduce antibodies from Phanes Therapeutics, an American biotech company, for the development of multiple bispecific antibodies.

Hanmi said Tuesday that it would apply Phanes' antibodies to Pentambody, a next-generation, bispecific antibody platform developed by Beijing Hanmi Pharmaceutical, that allows an antibody to simultaneously bind two different targets for both immuno-oncology therapy and targeted therapy.

Phanes, based in San Diego, is known for strong innovative drug discovery and development programs in metabolic complications and oncology areas. Hanmi said Tuesday that it is in charge of research, development, production and commercialization of a new dual antibody. They would allocate profits according to future commercialization.

Hanmin has seen a series of failures in its new drug development. In October 2016, Boehringer Ingelheim walked away from its $730 million partnership with Hanmi over safety concerns of Olita (Olmutinib) during clinical trials. Hanmi stopped the development of Olita, which used to be touted as a "breakthrough therapy" for patients who have developed a tolerance to existing lung cancer treatments.

In January this year, Eli Lilly and Company, a U.S. pharmaceutical company, returned its right to develop and commercialize Hanmi's new drug candidate for the treatment of immune diseases because interim results showed a lack of efficacy. They had studied the effects of a Bruton's tyrosine kinase (BTK) inhibitor in patients with rheumatoid arthritis to see if it has an effect on prevalent autoimmune diseases.

In July, Janssen Pharmaceutica, a pharmaceutical company based in Belgium, gave up clinical research into a candidate substance developed by Hanmi for a new drug that helps diabetes patients lose weight and control blood sugar.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Hanmi partners with RAPT Therapeutics to develop and commercialize FLX475 for cancer treatment.
    Hanmi partners with RAPT Therapeutics to develop and commerc…
  • .Janssen finally gives up clinical research into Hanmis new drug candidate .
    Janssen finally gives up clinical research into Hanmi's new …
  • .U.S. partner Lily completely walks away from drug deal with Hanmi Pharmaceutical.
    U.S. partner Lily completely walks away from drug deal with …
  • .Hanmi Pharmaceuticals HM43239 anti-cancer drug wins FDA designation.
    Hanmi Pharmaceutical's HM43239 anti-cancer drug wins FDA des…
  • .Prosecutors raid drug maker Hanmis office over short-selling scandal.
    Prosecutors raid drug maker Hanmi's office over short-sellin…

Real Time Photo News

  • .​WINNERs Song Mino to officially debut as artist at exhibition for emerging artists.

    ​WINNER's Song Mino to officially debut as artist at exhibition for emerging artists

  • .Netflix to release new original K-drama content in February next year.

    Netflix to release new original K-drama content in February next year

  • .Singer Kang Daniel updates fans on lawsuit against cyberbullies.

    Singer Kang Daniel updates fans on lawsuit against cyberbullies

  • .Rapper DinDin thanks former 2NE1 member Sandara for G-Dragons limited edition shoes .

    Rapper DinDin thanks former 2NE1 member Sandara for G-Dragon's limited edition shoes

  • .Singer Ailee drops winter-themed ballad song Sweater.

    Singer Ailee drops winter-themed ballad song 'Sweater'

Latest News

more+

  • Doosan Group selects Amazon's cloud service as main tool for digital transformation
  • ​WINNER's Song Mino to officially debut as artist at exhibition for emerging artists
  • Merger of food delivery service apps face objection by franchise shop owners
  • Toss fintech operator wins temporary approval to launch new internet-only bank
  • Netflix to release new original K-drama content in February next year
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view